Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Free Radic Biol Med. 2021 Jan 12;170:150–178. doi: 10.1016/j.freeradbiomed.2020.12.452

Table 3.

Therapeutic agents targeting mitochondrial fission/fusion mediators in PAH and cancer.

Therapy Category Target Tested disease(s)
siDrp1 siRNA Drp1 PAH [214], lung cancer
mdivi-1 Small compound Drp1 GTPase domain PAH [214], lung cancer [211], brain tumors [240], breast cancer [248, 249], melanoma [250]
P110 Peptide Drp1-FIS1 interaction RV-IR injury [235]
Drpitor1a Small compound Drp1 GTPase domain Lung cancer [262], RV-IR injury [262]
siMiD49/51 siRNA MiD49, MiD51 PAH [212], lung cancer [213], breast cancer [213]
miR-34a-3p miRNA MiD49, MiD51 PAH [212], lung cancer [213], breast cancer [213]
Adv-Mfn2 Adenovirus Mfn2 PAH [216], lung cancer [211]
leflunomide Small compound Mfn2 Mouse spontaneous tumors [279]
miR-125a miRNA Mfn2 PANC-1 pancreatic cancer cell [287]